Dublin, Jan. 22, 2016 -- Research and Markets (http://www.researchandmarkets.com/research/r9hfrx/nanobiotechnology) has announced the addition of Jain PharmaBiotech's new report "Nanobiotechnology Applications, Markets and Companies" to their offering.
An increasing use of nanobiotechnology by the pharmaceutical and biotechnology industries is anticipated. Nanotechnology will be applied at all stages of drug development - from formulations for optimal delivery to diagnostic applications in clinical trials. Many of the assays based on nanobiotechnology will enable high-throughput screening. Some of nanostructures such as fullerenes are themselves drug candidates as they allow precise grafting of active chemical groups in three-dimensional orientations. The most important pharmaceutical applications are in drug delivery. Apart from offering a solution to solubility problems, nanobiotechnology provides and intracellular delivery possibilities. Skin penetration is improved in transdermal drug delivery. A particularly effective application is as nonviral gene therapy vectors. Nanotechnology has the potential to provide controlled release devices with autonomous operation guided by the needs.
Nanomedicine is now within the realm of reality starting with nanodiagnostics and drug delivery facilitated by nanobiotechnology. Miniature devices such as nanorobots could carry out integrated diagnosis and therapy by refined and minimally invasive procedures, nanosurgery, as an alternative to crude surgery. Applications of nanobiotechnology are described according to various therapeutic systems. Nanotechnology will markedly improve the implants and tissue engineering approaches as well. Of the over 1,000 clinical trials of nanomedicines, approximately 100 are selected and tabulated in major therapeutic areas. Other applications such as for management of biological warfare injuries and poisoning are included. Contribution of nanobiotechnology to nutrition and public health such as supply of purified water are also included.
There is some concern about the safety of nanoparticles introduced in the human body and released into the environment. Research is underway to address these issues. As yet there are no FDA directives to regulate nanobiotechnology but as products are ready to enter market, these are expected to be in place.
Future nanobiotechnology markets are calculated on the basis of the background markets in the areas of application and the share of this market by new technologies and state of development at any given year in the future. This is based on a comprehensive and thorough review of the current status of nanobiotechnology, research work in progress and anticipated progress. There is definite indication of large growth of the market but it will be uneven and cannot be plotted as a steady growth curve. Marketing estimates are given according to areas of application, technologies and geographical distribution starting with 2015. The largest expansion is expected between the years 2020 and 2025.
Profiles of 248 companies, out of over 500 involved in this area, are included in the last chapter along with their 180 collaborations. The report is supplemented with 43 Tables, 27 figures and 820 references to the literature.
Key Topics Covered:
Executive Summary
1. Introduction
2. Nanotechnologies
3. Nanotechnologies for Basic Research Relevant to Medicine
4. Nanomolecular Diagnostics
5. Nanopharmaceuticals
6. Role of Nanotechnology in Biological Therapies
7. Nanodevices & Techniques for Clinical Applications
8. Nanooncology
9. Nanoneurology
10. Nanocardiology
11. Nanopulmonology
12. Nanoorthopedics
13. Nanoophthalmology
14. Nanomicrobiology
15. Miscellaneous Healthcare Applications of Nanobiotechnology
16. Nanobiotechnology and Personalized Medicine
17. Nanotoxicology
18. Ethical and Regulatory Aspects of Nanomedicine
19. Research and Future of Nanomedicine
20. Nanobiotechnology Markets
21. References
For more information visit http://www.researchandmarkets.com/research/r9hfrx/nanobiotechnology
Source: Jain PharmaBiotech
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Nanotechnology


Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs
UPS and Teamsters Reach Agreement to Limit Driver Severance Program
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58%
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 



